Streetbeat News

Regulatory

BFRG

BullFrog AI has announced a US patent for novel prodrugs of mebendazole, which are used in treating cancer. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:59 am

SPY

VGK

Russia's lower house of parliament has voted to raise the upper age limit for conscription to 30. This could potentially impact the country's military manpower and geopolitical stance.

Portfolio Pulse from Charles Gross

July 25, 2023 | 11:57 am

BFRG

Bullfrog AI Holdings has announced that the United States Patent and Trademark Office will issue U.S. Patent No. 11,712,435 on August 1, 2023. The patent protects the company's novel prodrugs derived from Mebendazole and their use in treating cancers and other diseases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:56 am

BABA

Alibaba Group Holding Limited (NYSE:BABA) has been in the spotlight due to its organizational and management restructuring aimed at unlocking shareholder value. The company also received relief from a regulatory crackdown with a final penalty for Ant Group. Alibaba has decided not to reduce its Ant Group stake and reported progress in cutting emissions. The company reinstated Jiang Fan as the international business unit leader. Alibaba's shares traded higher by 1.82% at $98.10 premarket on Tuesday.

Portfolio Pulse from Anusuya Lahiri

July 25, 2023 | 11:48 am

FXI

GM

GM's CFO has stated that the China market continues to be challenging due to slower recovery and pricing competition.

Portfolio Pulse from Charles Gross

July 25, 2023 | 11:33 am

ABBV

Health Canada has approved AbbVie's Rinvoq for moderately to severely active ulcerative colitis in adult patients who have demonstrated prior treatment failure. The approval is for the 45 mg induction dose and the 15 mg and 30 mg maintenance doses.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:15 am

STOK

Stoke Therapeutics has announced new safety and efficacy data from its STK-001 drug in two ongoing Phase 1/2A studies and the open-label extension study in children and adolescents with Dravet Syndrome. The data suggests clinical benefits.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:12 am

LRMR

The FDA has cleared Larimar Therapeutics' Phase 2 dose exploration trial of CTI-1601 for Friedreich's Ataxia to proceed to the 50 mg cohort. The initiation of an open-label extension trial with 25 mg daily dosing is expected in Q1 2024, with interim data expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:07 am

APLT

Applied Therapeutics announced that a pre-NDA meeting will be held this summer to discuss a potential NDA submission for AT-007.

Portfolio Pulse from Bill Haddad

July 25, 2023 | 11:06 am

TARS

The FDA has approved Tarsus Pharmaceuticals' Xdemvy (Lotilaner Ophthalmic Solution, formerly TP-03) 0.25% for Demodex Blepharitis. The drug is expected to be available by prescription by the end of August 2023.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 11:04 am